Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697251 | 1.00 | SCN9A (0.61) | SCN9ASCN3ABCHEMAOBPARP15 | |
| SCHEMBL1697231 | 1.00 | SCN9A (0.61) | SCN9ASCN3ABCHEMAOBPARP15 | |
| SCHEMBL8638250 | 0.91 | SCN9A (0.50) | SCN9ASCN3ABCHENPC1RAB9A | |
| SCHEMBL2939300 | 0.83 | MCL1 (0.44) | SCN9ARAB9ALMNAKMT2AKDM4E | |
| SCHEMBL2934213 | 0.83 | MCL1 (0.44) | SCN9ARAB9ALMNAKMT2AKDM4E | |
| SCHEMBL2933337 | 0.83 | MCL1 (0.44) | SCN9ARAB9ALMNAKMT2AKDM4E | |
| SCHEMBL1672184 | 0.81 | MAOB (0.62) | SCN9ABCHEMAOBMAOA | |
| SCHEMBL1665718 | 0.81 | MAOB (0.62) | SCN9ABCHEMAOBMAOA | |
| SCHEMBL2940856 | 0.81 | MAOB (0.62) | SCN9ABCHEMAOBMAOA | |
| Water SCHEMBL1672445 | 0.81 | MAOB (0.61) | SCN9ABCHEMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257842-B1 | THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2020-11-18 | — | — | EP | disclosed |
| US-9856207-B2 | Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2018-01-02 | — | — | US | disclosed |
| EP-3257842-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| EP-2229351-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2017-11-08 | — | — | EP | disclosed |
| US-20170029365-A1 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE SALTS SUBSTANTIALLY FREE FROM IMPURITIES HAVING GENOTOXIC EFFECTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2017-02-02 | — | — | US | disclosed |
| US-9505708-B2 | Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-11-29 | — | — | US | disclosed |
| EP-2474521-B1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | NEWRON PHARM SPA (IT) | 2016-08-10 | — | — | EP | disclosed |
| EP-2563355-B1 | Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers | NEWRON PHARM SPA (IT) | 2016-06-08 | — | — | EP | disclosed |
| EP-2029524-B1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | NEWRON PHARM SPA (IT) | 2014-11-26 | — | — | EP | disclosed |
| US-8846763-B2 | High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-09-30 | — | — | US | disclosed |
| EP-2229351-A1 | PROCESS FOR THE PRODUCTION OF 2-Ý4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO¨PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| EP-1809271-B9 | USE OF (R)-(HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS | NEWRON PHARM SPA (IT) | 2010-09-22 | — | — | EP | disclosed |
| EP-1809271-B1 | USE OF (R)-(HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS | NEWRON PHARM SPA (IT) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009074478-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | US | disclosed |
| EP-2029524-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | Newron Pharmaceuticals S.p.A. (IT) | 2009-03-04 | — | — | EP | disclosed |
| US-20080096965-A1 | (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-04-24 | — | — | US | disclosed |
| WO-2007147491-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLU0R0BENZYL0XY) BENZYLAMIN0] PROPAN AMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-12-27 | — | — | WO | disclosed |
| EP-1809271-A2 | (HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006027052-A2 | (HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | SCN9A 407/4885SCN3A 272/4885BCHE 443/4885 |
| US-20170029365-A1 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE SALTS SUBSTANTIALLY FREE FROM IMPURITIES HAVING GENOTOXIC EFFECTS | RALA, KRAS, RAP2C | SCN9A 2723/4885SCN3A 1079/4885BCHE 1340/4885 |
| US-20080096965-A1 | (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators | CACNA1E, TRPV1, KCNN2 | SCN9A 111/4885SCN3A 62/4885BCHE 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.